We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Epizyme (EPZM) Q4 Earnings Miss Estimates, Revenues Beat
Read MoreHide Full Article
Epizyme Inc. incurred a loss of 59 cents per share in fourth-quarter 2019, wider than the Zacks Consensus Estimate of a loss of 51 cents and the year-ago loss of 29 cents.
Quarter in Detail
Collaboration revenues in fourth-quarter 2019, earned as part of the company’s alliance with Boehringer Ingelheim, were $4.3 million compared with $9.7 million in the prior-year period. Revenues beat the Zacks Consensus Estimate of $3 million.
Shares of Epizyme have increased 57.3% in the past year against the industry’s 5.8% decline.
On Jan 23, 2020, the FDA granted accelerated approval to tazemetostat for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced Epithelioid Sarcoma (ES) not eligible for complete resection. It will be marketed under the brand name Tazverik. Tazverik became commercially available to patients on Feb 1, 2020.
Research and development expenses increased 75.7% year over year to $38.3 million in the quarter. The increase is due to the initiation of the global confirmatory studies in ES and FL and early expansion of the tazemetostat program into new indications and combinations
General and administrative expenses were $23.5 million in the quarter, up 92.6% from the year-ago period due to launch and commercialization of Tazverik for the ES indication, as well as initial expansion to prepare for FL commercialization in the United States.
Epizyme had $381.1 million of cash, cash equivalents and marketable securities as of Dec 31, 2019 compared with $240.3 million in the corresponding period of 2018. The company expects its cash runway to extend into at least 2022.
2019 Results
Epizyme posted a loss of $1.93 in 2019, wider than the loss of $1.72 in 2018.
Collaboration revenues in 2019 came in at$23.8 million, up 9.7% year over year.
Pipeline Update
The FDA accepted the company’s supplemental NDA (sNDA) for filing for the accelerated approval of Tazverik for a proposed indication of patients with relapsed or refractory FL who have received at least two prior lines of systemic therapy. The FDA granted Priority Review for the sNDA and set an action date of Jun 18, 2020.
Expected Milestones in 2020
The company expects to complete the safety portion of the ongoing global, phase Ib/III confirmatory study assessing Tazverik in combination with doxorubicin compared with doxorubicin plus placebo as a front-line treatment for ES, and advance into the efficacy portion of the study.
The company also expects to complete the safety portion of the ongoing global phase Ib/III confirmatory study assessing Tazverik in combination with "R2" (Revlimid plus Rituximab) compared with R2 plus placebo in the second-line treatment setting for FL and advance into the efficacy portion of the study.
Aduro’s loss per share estimates for 2020 have narrowed from 86 cents to 77 cents in the past 60 days.
Guardant’s loss per share estimates for 2020 have narrowed from $1.18 to $1.13 in the past 60 days. The company delivered a trailing four-quarter positive earnings surprise of 39.21%, on average.
Regeneron’s earnings per share estimates for 2020 have increased from $26.76 to $28.31 and from $28.61 to $28.93 for 2021 in the past 60 days. The company beat earnings estimates in three of the trailing four quarters while missed in one, delivering an average positive surprise of 1.44%.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Epizyme (EPZM) Q4 Earnings Miss Estimates, Revenues Beat
Epizyme Inc. incurred a loss of 59 cents per share in fourth-quarter 2019, wider than the Zacks Consensus Estimate of a loss of 51 cents and the year-ago loss of 29 cents.
Quarter in Detail
Collaboration revenues in fourth-quarter 2019, earned as part of the company’s alliance with Boehringer Ingelheim, were $4.3 million compared with $9.7 million in the prior-year period. Revenues beat the Zacks Consensus Estimate of $3 million.
Shares of Epizyme have increased 57.3% in the past year against the industry’s 5.8% decline.
On Jan 23, 2020, the FDA granted accelerated approval to tazemetostat for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced Epithelioid Sarcoma (ES) not eligible for complete resection. It will be marketed under the brand name Tazverik. Tazverik became commercially available to patients on Feb 1, 2020.
Research and development expenses increased 75.7% year over year to $38.3 million in the quarter. The increase is due to the initiation of the global confirmatory studies in ES and FL and early expansion of the tazemetostat program into new indications and combinations
General and administrative expenses were $23.5 million in the quarter, up 92.6% from the year-ago period due to launch and commercialization of Tazverik for the ES indication, as well as initial expansion to prepare for FL commercialization in the United States.
Epizyme had $381.1 million of cash, cash equivalents and marketable securities as of Dec 31, 2019 compared with $240.3 million in the corresponding period of 2018. The company expects its cash runway to extend into at least 2022.
2019 Results
Epizyme posted a loss of $1.93 in 2019, wider than the loss of $1.72 in 2018.
Collaboration revenues in 2019 came in at$23.8 million, up 9.7% year over year.
Pipeline Update
The FDA accepted the company’s supplemental NDA (sNDA) for filing for the accelerated approval of Tazverik for a proposed indication of patients with relapsed or refractory FL who have received at least two prior lines of systemic therapy. The FDA granted Priority Review for the sNDA and set an action date of Jun 18, 2020.
Expected Milestones in 2020
The company expects to complete the safety portion of the ongoing global, phase Ib/III confirmatory study assessing Tazverik in combination with doxorubicin compared with doxorubicin plus placebo as a front-line treatment for ES, and advance into the efficacy portion of the study.
The company also expects to complete the safety portion of the ongoing global phase Ib/III confirmatory study assessing Tazverik in combination with "R2" (Revlimid plus Rituximab) compared with R2 plus placebo in the second-line treatment setting for FL and advance into the efficacy portion of the study.
Epizyme, Inc. Price, Consensus and EPS Surprise
Epizyme, Inc. price-consensus-eps-surprise-chart | Epizyme, Inc. Quote
Zacks Rank and Stocks to Consider
Currently, Epizyme is a Zacks Rank #3 (Hold) stock.
Some better-ranked stocks in the biotech sector include Aduro Biotech Inc. Guardant Health Inc. (GH - Free Report) and Regeneron Pharmaceuticals Inc. (REGN - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Aduro’s loss per share estimates for 2020 have narrowed from 86 cents to 77 cents in the past 60 days.
Guardant’s loss per share estimates for 2020 have narrowed from $1.18 to $1.13 in the past 60 days. The company delivered a trailing four-quarter positive earnings surprise of 39.21%, on average.
Regeneron’s earnings per share estimates for 2020 have increased from $26.76 to $28.31 and from $28.61 to $28.93 for 2021 in the past 60 days. The company beat earnings estimates in three of the trailing four quarters while missed in one, delivering an average positive surprise of 1.44%.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>